New study shows the ability of CD8+ cytotoxic T cells to penetrate a large target, which opens avenues to destroy solid cancers.
List view / Grid view
Filter the results
Redundancies have been discovered in the biochemical signalling pathways of immune cells which could impact cancer immunotherapy.
Researchers have found that certain immune cells aid in fighting tuberculosis bacteria, providing a new drug target.
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
Engineered T cell immunotherapy (such as chimeric antigen receptor T cell (CAR-T) and T cell receptor T cell (TCR-T) therapy), could potentially be used as a therapeutic strategy for tumour treatment.
Researchers have used single-cell sequencing to map the landscape of myeloid cells in tumours from patients with lung cancer...
The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…
Engineered T-cells that target NFAT and Nr4a proteins could help to prevent the exhaustion of T-cells during CAR-T immunotherapy...
Combination therapy with a CHK1 or PARP inhibitor, with an immune checkpoint inhibitor caused the regression of small cell lung cancer in all mice treated...
Sartorius Stedim Biotech introduces BIOSTAT® RM TX with Flexsafe® RM TX for producing consistent quality cellular products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.